An interim report of a study examining the combination of quizartinib with azacitidine has shown promising results, with a response observed in 69% of patients with relapsed or refractory MDS, chronic myelomonocytic leukemia or AML, including 4 of 7 patients that had received prior FLT3 TKI treatment [181]. Here, FLT3 is linked to myelodysplastic syndrome.